Tempus AI (NASDAQ:TEM) Sees Large Volume Increase – Here’s What Happened

Shares of Tempus AI, Inc. (NASDAQ:TEM) saw unusually-high trading volume on Tuesday . Approximately 3,894,953 shares were traded during trading, a decline of 24% from the previous session’s volume of 5,108,802 shares.The stock last traded at $59.27 and had previously closed at $59.00.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. William Blair reiterated a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Bank of America raised their target price on shares of Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. Piper Sandler decreased their target price on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Needham & Company LLC raised their price target on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Finally, Loop Capital reduced their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.18.

Tempus AI Stock Performance

The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The company’s 50-day moving average price is $56.88 and its 200 day moving average price is $51.40.

Insider Transactions at Tempus AI

In related news, major shareholder Bradley A. Keywell sold 170,720 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $35.45, for a total transaction of $6,052,024.00. Following the completion of the transaction, the insider now directly owns 15,993,729 shares of the company’s stock, valued at approximately $566,977,693.05. This trade represents a 1.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 3,240,234 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.75, for a total transaction of $190,363,747.50. Following the completion of the sale, the chief executive officer now owns 4,895,589 shares in the company, valued at approximately $287,615,853.75. The trade was a 39.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,598,969 shares of company stock valued at $317,194,162 over the last 90 days.

Institutional Trading of Tempus AI

Large investors have recently added to or reduced their stakes in the company. Operose Advisors LLC bought a new stake in Tempus AI in the fourth quarter worth $25,000. First Horizon Advisors Inc. purchased a new position in Tempus AI in the third quarter worth about $30,000. Farther Finance Advisors LLC bought a new stake in Tempus AI during the fourth quarter worth approximately $34,000. Prestige Wealth Management Group LLC raised its position in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares during the period. Finally, NewEdge Advisors LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at approximately $49,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.